KR100886990B1 - 비정상적인 세포성장의 치료를 위한 피리미딘 유도체 - Google Patents
비정상적인 세포성장의 치료를 위한 피리미딘 유도체 Download PDFInfo
- Publication number
- KR100886990B1 KR100886990B1 KR1020067023767A KR20067023767A KR100886990B1 KR 100886990 B1 KR100886990 B1 KR 100886990B1 KR 1020067023767 A KR1020067023767 A KR 1020067023767A KR 20067023767 A KR20067023767 A KR 20067023767A KR 100886990 B1 KR100886990 B1 KR 100886990B1
- Authority
- KR
- South Korea
- Prior art keywords
- ylamino
- alkyl
- methyl
- trifluoromethyl
- dihydro
- Prior art date
Links
- 0 Nc1ccc(*C(C2)=O)c2c1 Chemical compound Nc1ccc(*C(C2)=O)c2c1 0.000 description 2
- IDRUEHMBFUJKAK-UHFFFAOYSA-N FC(c(c(Cl)n1)cnc1Cl)(F)F Chemical compound FC(c(c(Cl)n1)cnc1Cl)(F)F IDRUEHMBFUJKAK-UHFFFAOYSA-N 0.000 description 1
- LHTJEBJSHUCUDT-UHFFFAOYSA-N O=C(C1)Nc(cc2)c1cc2Nc1ncc(C(F)(F)F)c(Cl)n1 Chemical compound O=C(C1)Nc(cc2)c1cc2Nc1ncc(C(F)(F)F)c(Cl)n1 LHTJEBJSHUCUDT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57131204P | 2004-05-14 | 2004-05-14 | |
| US60/571,312 | 2004-05-14 | ||
| PCT/IB2005/001201 WO2005111023A1 (en) | 2004-05-14 | 2005-05-02 | Pyrimidine derivatives for the treatment of abnormal cell growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20070012477A KR20070012477A (ko) | 2007-01-25 |
| KR100886990B1 true KR100886990B1 (ko) | 2009-03-04 |
Family
ID=34966230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067023767A KR100886990B1 (ko) | 2004-05-14 | 2005-05-02 | 비정상적인 세포성장의 치료를 위한 피리미딘 유도체 |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1751143A1 (xx) |
| JP (1) | JP4099212B2 (xx) |
| KR (1) | KR100886990B1 (xx) |
| CN (2) | CN102127058A (xx) |
| AP (1) | AP2241A (xx) |
| AR (1) | AR049097A1 (xx) |
| AU (2) | AU2005243397A1 (xx) |
| BR (1) | BRPI0511138A (xx) |
| CA (1) | CA2566707A1 (xx) |
| CR (1) | CR8749A (xx) |
| EA (1) | EA200601796A1 (xx) |
| EC (1) | ECSP066997A (xx) |
| GE (1) | GEP20104875B (xx) |
| GT (1) | GT200500113A (xx) |
| IL (1) | IL178828A0 (xx) |
| MA (1) | MA28583B1 (xx) |
| MX (1) | MXPA06011890A (xx) |
| NL (2) | NL1029045C2 (xx) |
| NO (1) | NO20064576L (xx) |
| NZ (1) | NZ550448A (xx) |
| PA (1) | PA8632601A1 (xx) |
| PE (1) | PE20060240A1 (xx) |
| TN (1) | TNSN06370A1 (xx) |
| TW (1) | TWI303635B (xx) |
| UY (1) | UY28894A1 (xx) |
| WO (1) | WO2005111023A1 (xx) |
| ZA (1) | ZA200608394B (xx) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2566531A1 (en) * | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
| US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| JP4332590B2 (ja) * | 2005-12-21 | 2009-09-16 | ファイザー・プロダクツ・インク | 異常細胞増殖を治療するためのピリミジン誘導体 |
| CN103951658B (zh) * | 2007-04-18 | 2017-10-13 | 辉瑞产品公司 | 用于治疗异常细胞生长的磺酰胺衍生物 |
| CN101903357A (zh) * | 2007-07-17 | 2010-12-01 | 里格尔药品股份有限公司 | 作为pkc抑制剂的环状胺取代的嘧啶二胺 |
| JP2011505407A (ja) * | 2007-12-03 | 2011-02-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 過剰な又は異常な細胞増殖を特徴とする疾患を治療するためのジアミノピリジン |
| HUE035029T2 (en) * | 2008-05-21 | 2018-03-28 | Ariad Pharma Inc | Kinase inhibitor phosphorus derivatives |
| US8410126B2 (en) * | 2009-05-29 | 2013-04-02 | Boehringer Ingelheim International Gmbh | Pyrimidine inhibitors of PKTK2 |
| JP5539518B2 (ja) | 2009-08-14 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ２−アミノ−５−トリフルオロメチルピリミジン誘導体の位置選択的調製 |
| US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| JPWO2014174745A1 (ja) * | 2013-04-26 | 2017-02-23 | 国立大学法人京都大学 | Ｅｇ５阻害剤 |
| CN109608444B (zh) * | 2018-11-27 | 2022-02-11 | 中国药科大学 | 含异吲哚啉酮的erk抑制剂及其制备方法与用途 |
| CN111732548B (zh) * | 2020-06-11 | 2022-06-17 | 浙江大学 | N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途 |
| WO2024140671A1 (zh) * | 2022-12-29 | 2024-07-04 | 南京昕瑞再生医药科技有限公司 | 一种稠三环类衍生物、包含其的药物组合物及其用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999021859A1 (en) * | 1997-10-10 | 1999-05-06 | Glaxo Group Limited | Azaoxindole derivatives |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| US6653308B2 (en) | 2001-02-15 | 2003-11-25 | Sugen, Inc. | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS20060097A (xx) * | 2002-12-20 | 2008-11-28 | Pfizer Products Inc., | Derivati pirimidina za lečenje nekontrolisanog rasta ćelija |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
-
2005
- 2005-05-02 CA CA002566707A patent/CA2566707A1/en not_active Abandoned
- 2005-05-02 WO PCT/IB2005/001201 patent/WO2005111023A1/en active Application Filing
- 2005-05-02 CN CN2011100212904A patent/CN102127058A/zh active Pending
- 2005-05-02 CN CNA2005800155302A patent/CN1953974A/zh active Pending
- 2005-05-02 GE GEAP20059703A patent/GEP20104875B/en unknown
- 2005-05-02 AU AU2005243397A patent/AU2005243397A1/en not_active Abandoned
- 2005-05-02 NZ NZ550448A patent/NZ550448A/en unknown
- 2005-05-02 KR KR1020067023767A patent/KR100886990B1/ko active IP Right Grant
- 2005-05-02 JP JP2007512557A patent/JP4099212B2/ja active Active
- 2005-05-02 BR BRPI0511138-2A patent/BRPI0511138A/pt not_active IP Right Cessation
- 2005-05-02 AP AP2006003790A patent/AP2241A/xx active
- 2005-05-02 MX MXPA06011890A patent/MXPA06011890A/es unknown
- 2005-05-02 EP EP05732043A patent/EP1751143A1/en not_active Withdrawn
- 2005-05-02 EA EA200601796A patent/EA200601796A1/ru unknown
- 2005-05-11 PA PA20058632601A patent/PA8632601A1/es unknown
- 2005-05-11 TW TW094115237A patent/TWI303635B/zh active
- 2005-05-12 PE PE2005000534A patent/PE20060240A1/es not_active Application Discontinuation
- 2005-05-12 UY UY28894A patent/UY28894A1/es not_active Application Discontinuation
- 2005-05-13 AR ARP050101969A patent/AR049097A1/es not_active Application Discontinuation
- 2005-05-13 NL NL1029045A patent/NL1029045C2/nl active Search and Examination
- 2005-05-13 GT GT200500113A patent/GT200500113A/es unknown
-
2006
- 2006-05-19 NL NL1031845A patent/NL1031845C2/nl active Search and Examination
- 2006-10-06 ZA ZA200608394A patent/ZA200608394B/xx unknown
- 2006-10-09 NO NO20064576A patent/NO20064576L/no not_active Application Discontinuation
- 2006-10-23 IL IL178828A patent/IL178828A0/en unknown
- 2006-11-13 CR CR8749A patent/CR8749A/es not_active Application Discontinuation
- 2006-11-13 TN TNP2006000370A patent/TNSN06370A1/fr unknown
- 2006-11-13 EC EC2006006997A patent/ECSP066997A/es unknown
- 2006-11-14 MA MA29452A patent/MA28583B1/fr unknown
-
2009
- 2009-11-13 AU AU2009238255A patent/AU2009238255A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999021859A1 (en) * | 1997-10-10 | 1999-05-06 | Glaxo Group Limited | Azaoxindole derivatives |
| US6653308B2 (en) | 2001-02-15 | 2003-11-25 | Sugen, Inc. | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100886990B1 (ko) | 비정상적인 세포성장의 치료를 위한 피리미딘 유도체 | |
| US7109337B2 (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
| EP1625121B1 (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
| US7145008B2 (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
| US7208499B2 (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
| KR101060051B1 (ko) | 비정상적인 세포 성장을 치료하기 위한 피리미딘 유도체 | |
| US20060205945A1 (en) | Pyrimidine derivatives for the treatment of abnormal cell growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E90F | Notification of reason for final refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20130305 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20140211 Year of fee payment: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20150224 Year of fee payment: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20160211 Year of fee payment: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20170221 Year of fee payment: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20180221 Year of fee payment: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20190212 Year of fee payment: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20200214 Year of fee payment: 12 |